Tag: Cardiac Dimensions

Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management

Guidelines support the Carillon Mitral Contour System® for the treatment of heart failure patients with secondary functional mitral regurgitation KIRKLAND, Wash., Sept. 22, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their […]

Cardiac Dimensions® Announces Launch of Its Optimized U.S. Pivotal Trial – The EMPOWER Trial

International Study to Evaluate Innovative Minimally Invasive Treatment for Heart Failure With Early-Stage Functional Mitral Regurgitation   KIRKLAND, Wash., Aug. 20, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the launch of the U.S. […]

Data Published in “JACC Heart Failure”Show Benefit of Carillon Device to Patients Suffering from Functional Mitral Regurgitation & Severe Left Ventricular

On behalf of Cardiac Dimensions, please find key outcomes of the analysis “Percutaneous Mitral-Valve Annuloplasty Versus Optimal Medical Therapy in Patients with Secondary Mitral-Regurgitation and Severe Left-Ventricular Enlargement” published in this month’s JACC: Heart Failure. The manuscript can be viewed here: https://cardiacdimensions.com/wp-content/uploads/docs/Anker-Complete-Publication_May-2021.pdf Key outcomes of the analysis are as follows — in the Carillon […]

Cardiac Dimensions Announces Two New Meta-Analysis Publications Showing Statistically Significant and Clinically Meaningful Benefits to Heart Failure Patients Suffering from Functional Mitral Regurgitation

KIRKLAND, Wash., April 7, 2021 /PRNewswire/ — Cardiac Dimensions announced a published second individual patient data meta–analysis demonstrating clinically significant outcomes for the Carillon Mitral Contour System®. This publication, in addition to the several others recently published on the Carillon device, continues the series of excellent results for this transcatheter-based indirect annuloplasty device. […]

Cardiac Dimensions Welcomes Robert White to its Board of Directors

KIRKLAND, Wash., April 6, 2021 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert White as an independent director to its Board of Directors. Mr. White is a veteran medical technology executive, innovator […]

Percutaneous Coronary Sinus–Based Mitral Valve Annuloplasty in Atrial Functional Mitral Regurgitation

Atrial functional mitral regurgitation (aFMR) is associated with left atrial (LA) and mitral annular dilatation most often caused by atrial fibrillation or heart failure with preserved ejection fraction (HFpEF). (A) Echocardiographic assessment, (B) functional mitral regurgitation classification, (C) New York Heart Association classification, and (D) mitral annulus diameter at baseline, […]

Cardiac Dimensions Announces up to 7.5 Year Data on the Carillon® Mitral Contour System

Have you seen the exciting new publication by Dr. Janusz Lipiecki and team, Long-term prognosis of patients treated by coronary sinus-based percutaneous annuloplasty: single centre experience, published in ESC Heart Failure 2020? This publication is Cardiac Dimension’s sixth this year! The company continues to release data which confirms the Carillon Mitral Contour System’s importance in the treatment of heart […]

Cardiac Dimensions Announces $17.5 Million Series C Financing to Accelerate Sales Expansion of The Carillon Mitral Contour System®

KIRKLAND, Wash., Sept. 29, 2020 /PRNewswire/ — Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the company has closed a $17.5 million Series C financing. All existing shareholders participated in the round including Aperture Venture Partners, Arboretum Ventures, Hostplus, […]

Cardiac Dimensions Announces Australian Therapeutic Goods Administration’s Approval of the Carillon System for the Treatment of Functional Mitral Regurgitation

KIRKLAND, Wash., Sept. 2, 2020 /PRNewswire/ — Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the Therapeutic Goods Administration (TGA) has approved its Carillon Mitral Contour System®. The Carillon System is a right heart transcatheter mitral valve […]

New Data Confirms Cardiac Dimensions’ Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation

Pooled Analysis of Prospective Studies Presented during Late Breaking Trials Session at CRT 2020 KIRKLAND, Wash., Feb. 25, 2020 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the findings of a post hoc analysis of […]